Clinical Trial Update: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating talazoparib in combination with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Talzenna (talazoparib)
• Xtandi (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: mCRPC | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-17